-DOCSTART- -X- O
Glycyrrhizin -X- _ B-Intervention
( -X- _ I-Intervention
GL -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
known -X- _ O
to -X- _ O
have -X- _ O
various -X- _ O
immunomodulating -X- _ O
activities -X- _ O
and -X- _ O
has -X- _ O
long -X- _ O
been -X- _ O
used -X- _ O
clinically -X- _ O
as -X- _ O
an -X- _ O
anti-allergic -X- _ O
and -X- _ O
anti-hepatitis -X- _ O
agent. -X- _ O
While -X- _ O
the -X- _ O
potency -X- _ O
of -X- _ O
GL -X- _ O
against -X- _ O
lung -X- _ O
inflammatory -X- _ O
diseases -X- _ O
has -X- _ O
been -X- _ O
expected -X- _ O
, -X- _ O
the -X- _ O
effect -X- _ O
of -X- _ O
GL -X- _ O
on -X- _ O
the -X- _ O
lung -X- _ O
has -X- _ O
been -X- _ O
poorly -X- _ O
understood. -X- _ O
Lung -X- _ B-Patient
fibroblasts -X- _ I-Patient
are -X- _ O
known -X- _ O
as -X- _ O
a -X- _ O
potent -X- _ O
producer -X- _ O
of -X- _ O
inflammatory -X- _ O
chemokines -X- _ O
, -X- _ O
IL-8 -X- _ O
and -X- _ O
eotaxin -X- _ O
1 -X- _ O
, -X- _ O
by -X- _ O
which -X- _ O
neutrophils -X- _ O
and -X- _ O
eosinophils -X- _ O
are -X- _ O
strongly -X- _ O
attracted -X- _ O
during -X- _ O
inflammation. -X- _ O
Therefore -X- _ O
, -X- _ O
we -X- _ O
studied -X- _ O
the -X- _ O
effects -X- _ O
of -X- _ O
GL -X- _ O
on -X- _ O
the -X- _ O
production -X- _ O
of -X- _ O
these -X- _ O
chemokines -X- _ O
using -X- _ O
a -X- _ O
human -X- _ B-Patient
fetal -X- _ I-Patient
lung -X- _ I-Patient
fibroblast -X- _ I-Patient
cell -X- _ I-Patient
line -X- _ I-Patient
, -X- _ I-Patient
HFL-1 -X- _ I-Patient
, -X- _ O
stimulated -X- _ O
with -X- _ O
TNF-α -X- _ O
and -X- _ O
IL-4. -X- _ O
Moreover -X- _ O
, -X- _ O
we -X- _ O
examined -X- _ O
the -X- _ O
structure–activity -X- _ O
relationships -X- _ O
of -X- _ O
GL -X- _ O
to -X- _ O
explore -X- _ O
more -X- _ O
beneficial -X- _ O
compounds. -X- _ O
18α -X- _ O
, -X- _ O
β-GL -X- _ O
inhibited -X- _ O
IL-8 -X- _ O
dose-dependently -X- _ O
and -X- _ O
inhibited -X- _ O
eotaxin -X- _ O
1 -X- _ O
slightly. -X- _ O
18α -X- _ O
, -X- _ O
β-Glycyrrhetic -X- _ O
acid -X- _ O
( -X- _ O
GA -X- _ O
) -X- _ O
did -X- _ O
not -X- _ O
inhibit -X- _ O
IL-8 -X- _ O
but -X- _ O
inhibited -X- _ O
eotaxin -X- _ O
1. -X- _ O
The -X- _ O
effect -X- _ O
of -X- _ O
18α -X- _ O
, -X- _ O
β-glycyrrhetic -X- _ O
acid -X- _ O
monoglucuronide -X- _ O
( -X- _ O
MGA -X- _ O
) -X- _ O
resembled -X- _ O
that -X- _ O
of -X- _ O
18α -X- _ B-Outcome
, -X- _ I-Outcome
β-GL -X- _ I-Outcome
but -X- _ I-Outcome
was -X- _ I-Outcome
weaker. -X- _ I-Outcome
Both -X- _ I-Outcome
3β- -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2-O-β-d-glucopyranuronosyl-β-d- -X- _ I-Outcome
glucopyranuronosyl -X- _ I-Outcome
) -X- _ I-Outcome
oxy -X- _ I-Outcome
] -X- _ I-Outcome
-18β-11-deoxo-olean-12-en-30-oic -X- _ I-Outcome
acid -X- _ I-Outcome
( -X- _ I-Outcome
11-deoxo-GL -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
3β- -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2-O-β- -X- _ I-Outcome
d-glucopyranuronosyl-β-d-glucopyranuronosyl -X- _ I-Outcome
) -X- _ I-Outcome
oxy -X- _ I-Outcome
] -X- _ I-Outcome
-olean-11,13 -X- _ I-Outcome
, -X- _ I-Outcome
( -X- _ I-Outcome
18 -X- _ I-Outcome
) -X- _ I-Outcome
-dien-30-oic -X- _ I-Outcome
acid -X- _ I-Outcome
( -X- _ I-Outcome
hetero-GL -X- _ I-Outcome
) -X- _ I-Outcome
exhibited -X- _ I-Outcome
inhibitory -X- _ I-Outcome
activity -X- _ I-Outcome
with -X- _ I-Outcome
significant -X- _ I-Outcome
cytotoxicity. -X- _ I-Outcome
3β- -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2-O-β-d-Glucopyranuronosyl-β-d- -X- _ I-Outcome
glucopyranuronosyl -X- _ I-Outcome
) -X- _ I-Outcome
oxy -X- _ I-Outcome
] -X- _ I-Outcome
-18β-olean-9,12-dien-30-oic -X- _ I-Outcome
acid -X- _ I-Outcome
( -X- _ I-Outcome
homo-GL -X- _ I-Outcome
) -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
have -X- _ I-Outcome
cytotoxicity -X- _ I-Outcome
but -X- _ I-Outcome
its -X- _ I-Outcome
activity -X- _ I-Outcome
was -X- _ I-Outcome
mild -X- _ I-Outcome
like -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
18α -X- _ I-Outcome
, -X- _ I-Outcome
β-GL. -X- _ I-Outcome
3β- -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2-O-β-d-Glucopyranuronosyl-β-d- -X- _ I-Outcome
glucopyranuronosyl -X- _ I-Outcome
) -X- _ I-Outcome
oxy -X- _ I-Outcome
] -X- _ I-Outcome
-olean-11,13 -X- _ I-Outcome
( -X- _ I-Outcome
18 -X- _ I-Outcome
) -X- _ I-Outcome
-dien-30-ol -X- _ I-Outcome
( -X- _ I-Outcome
hetero-30-OH-GL -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
3β- -X- _ I-Outcome
[ -X- _ I-Outcome
( -X- _ I-Outcome
2-O-β-d- -X- _ I-Outcome
glucopyranuronosyl-β-d-glucopyranuronosyl -X- _ I-Outcome
) -X- _ I-Outcome
oxy -X- _ I-Outcome
] -X- _ I-Outcome
-18β-olean-9,12-dien-30-ol -X- _ I-Outcome
( -X- _ I-Outcome
homo-30-OH-GL -X- _ I-Outcome
) -X- _ I-Outcome
showed -X- _ I-Outcome
potent -X- _ I-Outcome
inhibitory -X- _ I-Outcome
effects -X- _ I-Outcome
, -X- _ I-Outcome
at -X- _ I-Outcome
concentrations -X- _ I-Outcome
lower -X- _ I-Outcome
than -X- _ I-Outcome
18α -X- _ I-Outcome
, -X- _ I-Outcome
β-GL -X- _ I-Outcome
with -X- _ I-Outcome
no -X- _ I-Outcome
significant -X- _ I-Outcome
cytotoxicity. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
GL-related -X- _ O
compounds -X- _ O
are -X- _ O
effective -X- _ O
in -X- _ O
reducing -X- _ O
chemokine -X- _ O
production -X- _ O
and -X- _ O
that -X- _ O
GL-modified -X- _ O
compounds -X- _ O
including -X- _ O
hetero-30-OH-GL -X- _ O
and -X- _ O
homo-30-OH-GL -X- _ O
appear -X- _ O
most -X- _ O
beneficial -X- _ O
in -X- _ O
view -X- _ O
of -X- _ O
their -X- _ O
inhibitory -X- _ O
capacity -X- _ O
with -X- _ O
less -X- _ O
cytotoxicity -X- _ O
. -X- _ O

